Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 8, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2017-04-25
DOI
10.3389/fimmu.2017.00469
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia
- (2017) Sieghart Sopper et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia
- (2017) Gabriel Etienne et al. JOURNAL OF CLINICAL ONCOLOGY
- Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML
- (2017) C Schütz et al. LEUKEMIA
- CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression
- (2016) Anuradha Tarafdar et al. BLOOD
- Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study
- (2016) Delphine Rea et al. BLOOD
- Moving treatment-free remission into mainstream clinical practice in CML
- (2016) Timothy P. Hughes et al. BLOOD
- Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma
- (2016) M. Carlsten et al. CLINICAL CANCER RESEARCH
- When to Consider Allogeneic Transplantation in CML
- (2016) Jerald Radich Clinical Lymphoma Myeloma & Leukemia
- Chronic myeloid leukemia: Relevance of cytogenetic and molecular assays
- (2016) Ayda Bennour et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- 'Trained immunity: consequences for lymphoid malignancies
- (2016) W. B. C. Stevens et al. HAEMATOLOGICA
- Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study
- (2016) S.-E. Lee et al. HAEMATOLOGICA
- Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia
- (2016) Mohamed El Missiry et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial
- (2016) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies
- (2016) M H Qazilbash et al. LEUKEMIA
- Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia
- (2016) M Ilander et al. LEUKEMIA
- The concept of treatment-free remission in chronic myeloid leukemia
- (2016) S Saußele et al. LEUKEMIA
- Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia
- (2016) Lauren Caldemeyer et al. LEUKEMIA & LYMPHOMA
- Immunological off-target effects of imatinib
- (2016) Laurence Zitvogel et al. Nature Reviews Clinical Oncology
- 'Trained immunity: consequences for lymphoid malignancies
- (2016) W. B. C. Stevens et al. HAEMATOLOGICA
- Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study
- (2016) S.-E. Lee et al. HAEMATOLOGICA
- Licensed and Unlicensed NK Cells: Differential Roles in Cancer and Viral Control
- (2016) Megan M. Tu et al. Frontiers in Immunology
- Editorial: Dendritic Cell and Macrophage Nomenclature and Classification
- (2016) Florent Ginhoux et al. Frontiers in Immunology
- Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study
- (2015) Silvia Mori et al. AMERICAN JOURNAL OF HEMATOLOGY
- KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategy
- (2015) D. T. Yeung et al. BLOOD
- Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients
- (2015) Giovanni Caocci et al. EXPERIMENTAL HEMATOLOGY
- Immunology of chronic myeloid leukemia: current concepts and future goals
- (2015) Vladimír Vonka et al. Expert Review of Clinical Immunology
- Increased regulatory T cells in acute lymphoblastic leukemia patients
- (2015) Siti-Zuleha Idris et al. Hematology
- Increase in myeloid-derived suppressor cells (MDSCs) associated with minimal residual disease (MRD) detection in adult acute myeloid leukemia
- (2015) Hui Sun et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia
- (2015) A Burchert et al. LEUKEMIA
- The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses
- (2015) L. Christiansson et al. MOLECULAR CANCER THERAPEUTICS
- Fate Mapping of Dendritic Cells
- (2015) Mateusz Pawel Poltorak et al. Frontiers in Immunology
- Effector Functions of Natural Killer Cell Subsets in the Control of Hematological Malignancies
- (2015) Angela Gismondi et al. Frontiers in Immunology
- Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial
- (2015) Jun Imagawa et al. Lancet Haematology
- Myeloid Derived Suppressor Cells in Chronic Myeloid Leukemia
- (2015) Cesarina Giallongo et al. Frontiers in Oncology
- A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias
- (2014) L. Dubrovsky et al. BLOOD
- CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs
- (2014) R. Jitschin et al. BLOOD
- Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease
- (2014) James O.J. Davies et al. CYTOTHERAPY
- Imatinib Mesylate Inhibits CD4+CD25+ Regulatory T Cell Activity and Enhances Active Immunotherapy against BCR-ABL- Tumors
- (2014) N. Larmonier et al. JOURNAL OF IMMUNOLOGY
- Cancer-Expanded Myeloid-Derived Suppressor Cells Induce Anergy of NK Cells through Membrane-Bound TGF- 1
- (2014) H. Li et al. JOURNAL OF IMMUNOLOGY
- Myeloid Derived Suppressor Cells (MDSCs) Are Increased and Exert Immunosuppressive Activity Together with Polymorphonuclear Leukocytes (PMNs) in Chronic Myeloid Leukemia Patients
- (2014) Cesarina Giallongo et al. PLoS One
- The stimulation of PD-L1-specific cytotoxic T lymphocytes can both directly and indirectly enhance antileukemic immunity
- (2014) S M Ahmad et al. Blood Cancer Journal
- Does the Immune System Naturally Protect Against Cancer?
- (2014) Alexandre Corthay Frontiers in Immunology
- The Role of Myeloid-Derived Suppressor Cells in Immune Ontogeny
- (2014) Soren Gantt et al. Frontiers in Immunology
- Myeloid-Derived Suppressor Cells as Therapeutic Target in Hematological Malignancies
- (2014) Kim De Veirman et al. Frontiers in Oncology
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
- (2013) M. Baccarani et al. BLOOD
- Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib
- (2013) T. P. Hughes et al. BLOOD
- Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling
- (2013) H. de Lavallade et al. BLOOD
- Monoclonal antibody targeting of IL-3 receptor with CSL362 effectively depletes CML progenitor and stem cells
- (2013) E. Nievergall et al. BLOOD
- Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
- (2013) D. M. Ross et al. BLOOD
- Large granular lymphocytosis during dasatinib therapy
- (2013) Zhi-Yuan Qiu et al. CANCER BIOLOGY & THERAPY
- Prognostic value of regulatory T cells in newly diagnosed chronic myeloid leukemia patients
- (2013) Asmaa M. Zahran et al. International Journal of Clinical Oncology
- The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies
- (2013) Li Shi et al. Journal of Hematology & Oncology
- Myeloid derived suppressor cells – a new therapeutic target in the treatment of cancer
- (2013) Robert Wesolowski et al. Journal for ImmunoTherapy of Cancer
- How I treat newly diagnosed chronic phase CML
- (2012) J. Cortes et al. BLOOD
- New insights into antigen specific immunotherapy for chronic myeloid leukemia
- (2012) Yangqiu Li et al. Cancer Cell International
- Indoleamine 2,3-dioxygenase, Tregs and Cancer
- (2012) D. H. Munn CURRENT MEDICINAL CHEMISTRY
- The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells
- (2012) Dennis Lindau et al. IMMUNOLOGY
- Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib
- (2012) Nicole Hassold et al. INTERNATIONAL JOURNAL OF CANCER
- Alternative expression of TCRζ related genes in patients with chronic myeloid leukemia
- (2012) Xianfeng Zha et al. Journal of Hematology & Oncology
- Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib
- (2012) Yoshiki Hayashi et al. LEUKEMIA & LYMPHOMA
- An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells
- (2011) A. Sergeeva et al. BLOOD
- Quantitative and functional analyses of CD4+CD25+FoxP3+ regulatory T cells in chronic phase chronic myeloid leukaemia patients at diagnosis and on imatinib mesylate
- (2011) Emmanuel Bachy et al. BRITISH JOURNAL OF HAEMATOLOGY
- Antigens in chronic myeloid leukemia: implications for vaccine development
- (2011) Michal Šmahel CANCER IMMUNOLOGY IMMUNOTHERAPY
- Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia
- (2011) N. Takahashi et al. HAEMATOLOGICA
- RestrictedTRBVrepertoire in CD4+and CD8+T‐cell subsets from CML patients
- (2011) Yangqiu Li et al. Hematology
- Expression of natural killer cell activating receptors in patients with chronic lymphocytic leukaemia
- (2011) Régis T. Costello et al. IMMUNOLOGY
- Improved outcome following allogeneic stem cell transplantation in chronic myeloid leukemia is associated with higher expression of BMI-1 and immune responses to BMI-1 protein
- (2011) A S M Yong et al. LEUKEMIA
- NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR–ABL-positive mice
- (2011) C I-U Chen et al. LEUKEMIA
- Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
- (2011) Vinod P Balachandran et al. NATURE MEDICINE
- Chronic Myeloid Leukemia Patients in Prolonged Remission following Interferon-α Monotherapy Have Distinct Cytokine and Oligoclonal Lymphocyte Profile
- (2011) Anna Kreutzman et al. PLoS One
- Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia
- (2010) P. G. Maslak et al. BLOOD
- Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy
- (2010) Peter Rohon et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- The PD-1 pathway in tolerance and autoimmunity
- (2010) Loise M. Francisco et al. IMMUNOLOGICAL REVIEWS
- Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion
- (2010) Yasunobu Nagata et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia
- (2010) Andreas Burchert et al. JOURNAL OF CLINICAL ONCOLOGY
- Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
- (2010) François-Xavier Mahon et al. LANCET ONCOLOGY
- Lck is a key target of imatinib and dasatinib in T-cell activation
- (2010) K C Lee et al. LEUKEMIA
- Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR
- (2010) D M Ross et al. LEUKEMIA
- Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease
- (2010) Giovanni D’Arena et al. LEUKEMIA RESEARCH
- Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA-DR−/low Myeloid-Derived Suppressor Cells and Decreased Level of Dendritic Cells in Patients with Multiple Myeloma
- (2010) M. K. Brimnes et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Chronic Myeloid Leukemia: A Historical Perspective
- (2010) John M. Goldman SEMINARS IN HEMATOLOGY
- A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS
- (2009) U. Keilholz et al. BLOOD
- Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression
- (2009) S. Mumprecht et al. BLOOD
- Myeloid-Derived Suppressor Cells Inhibit T-Cell Activation by Depleting Cystine and Cysteine
- (2009) M. K. Srivastava et al. CANCER RESEARCH
- Increased Frequency and Suppression by Regulatory T Cells in Patients with Acute Myelogenous Leukemia
- (2009) M. J. Szczepanski et al. CLINICAL CANCER RESEARCH
- Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
- (2009) J. S. Ko et al. CLINICAL CANCER RESEARCH
- Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF
- (2009) Luigi Dolcetti et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- TCRζchain expression in T cells from patients with CML
- (2009) Si Chen et al. Hematology
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
- (2009) Loise M. Francisco et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Regulation of NK Cell Function by Human Granulocyte Arginase
- (2009) J. Oberlies et al. JOURNAL OF IMMUNOLOGY
- Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
- (2009) S. Ostrand-Rosenberg et al. JOURNAL OF IMMUNOLOGY
- Mechanism Regulating Reactive Oxygen Species in Tumor-Induced Myeloid-Derived Suppressor Cells
- (2009) C. A. Corzo et al. JOURNAL OF IMMUNOLOGY
- Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy
- (2009) S Mustjoki et al. LEUKEMIA
- Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia
- (2008) K. Rezvani et al. BLOOD
- Development and dynamics of robust T-cell responses to CML under imatinib treatment
- (2008) C. I-U. Chen et al. BLOOD
- Human natural killer cells
- (2008) M. A. Caligiuri BLOOD
- Dasatinib inhibits the proliferation and function of CD4+CD25+regulatory T cells
- (2008) Fei Fei et al. BRITISH JOURNAL OF HAEMATOLOGY
- Myeloid-Derived Suppressor Cells Promote Cross-Tolerance in B-Cell Lymphoma by Expanding Regulatory T Cells
- (2008) P. Serafini et al. CANCER RESEARCH
- Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update
- (2008) R. Seggewiss et al. CYTOTHERAPY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started